JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles
Shenwan Hongyuan Group: Airlines continue to increase capacity, paying attention to signals and trends of rising ticket prices following the "anti-inner circle" trend.
Guosen: August household appliance retail growth is good, companies appearing at IFA demonstrate determination to go global.
CMSC International: Mainland medical equipment industry performance is expected to bottom out and rebound, suggesting attention be paid to two main themes of domestic substitution and overseas expansion.
Shenwan Hongyuan Group: Airlines continue to increase capacity, paying attention to signals and trends of rising ticket prices following the "anti-inner circle" trend.
Guosen: August household appliance retail growth is good, companies appearing at IFA demonstrate determination to go global.
CMSC International: Mainland medical equipment industry performance is expected to bottom out and rebound, suggesting attention be paid to two main themes of domestic substitution and overseas expansion.
